All In Biotech

Drug Trial Radar · NCT05628740

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

A Phase 1, Two Part, Placebo-controlled, Single Dose Study in Healthy Volunteers and Multiple Dose Study in Patients With Refractory Chronic Cough to Assess the Safety, Tolerability, and PK of NTX-1175 Administered Via Nebulizer (NOC-100) and Dry Powder Inhaler (NOC-110)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 7, 2022

Primary completion

Oct 25, 2022

Study completion Oct 25, 2022

Sponsor

Lead sponsor
Nocion TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 will evaluate the safety, tolerability and PK of single doses of three dose levels of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) compared to a single dose reference nebulizer (NOC-100) treatment in healthy participants. Part 2 will evaluate the safety, tolerability and PK of multiple doses of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) to participants with refractory chronic cough. Part 2 will also evaluate the treatment effect of multiple doses of one dose level of NTX-1175 drug substance administered by dry powder inhaler (NOC-110).

Conditions

  • Refractory Chronic Cough

Interventions

  • 3 mg NOC-100 (via nebulizer)Drug

    Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1

  • 1 mg NOC-110 (via DPI) [1x 1 mg capsule]Drug

    Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule

  • 3 mg NOC-110 (via DPI)Drug

    Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule

  • Placebo (via DPI)Drug

    Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule

  • 6 mg NOC-110 (via DPI)Drug

    Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule

  • Placebo (via DPI) [2x Placebo capsules]Drug

    Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of Treatment Emergent Adverse Events (TEAEs) following single doses of NOC-110 or placebo administered with a DPITime frame: Part 1- Screening through Day 23
  2. Number and severity of TEAE following repeat doses of NOC 110 compared to placebo in participants with chronic cough.Time frame: Part 2- Screening through Day 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Phoenix, Arizona

  • Clinical Site Partners

    Leesburg, Florida

  • Clinical Site Partners

    Winter Park, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.